Gleneagles Hospital has partnered with Medtronic India to inaugurate a dedicated Renal Denervation Therapy Centre at its Parel facility, offering a comprehensive interventional care solution for patients with resistant hypertension whose blood pressure remains uncontrolled despite multiple medications.

The new specialised centre combines advanced interventional technology with multidisciplinary clinical expertise to deliver structured assessment, detailed clinical evaluation, patient counselling, medication optimisation, and access to renal denervation therapy for eligible patients. The initiative aims to improve long-term blood pressure control and reduce the risk of serious complications such as heart attack, stroke, kidney failure and other cardiovascular events linked to uncontrolled high blood pressure.

Renal denervation therapy is a minimally invasive procedure that targets overactive sympathetic nerves in the renal arteries that contribute to persistent hypertension, providing an additional treatment option for patients who do not respond adequately to medications alone.

The centre’s clinical leadership includes Dr. Rahul Gupta, Director and Cardiologist; Dr. Bharat Shah, Director and Nephrologist; Dr. V. M. Reddy, Senior Consultant Cardiologist; and Dr. Prashant Rajput, Senior Consultant Nephrologist. Together, they will deliver personalised and coordinated care pathways integrating cardiology, nephrology, and internal medicine expertise.

“Resistant hypertension significantly increases the risk of severe cardiovascular complications. Renal denervation therapy offers a vital additional treatment option for well-selected patients whose blood pressure does not respond to medicines alone, while a structured multidisciplinary approach can help optimise outcomes,” said Dr. Rahul Gupta.

Dr. Bipin Chevale, CEO of Gleneagles Hospital, noted that patient education, lifestyle counselling, and continuous monitoring alongside advanced therapeutic options are key to long-term blood pressure control and improved patient outcomes.

Mandeep Singh Kumar, Managing Director and Vice President of Medtronic India, emphasised that the collaboration is designed to increase awareness of resistant hypertension and support improved diagnosis and management pathways by combining clinical expertise with evidence-based technology.

Uncontrolled hypertension continues to be a significant public health challenge in India, frequently linked to lifestyle factors such as stress, diet, obesity, sedentary behaviour and inadequate follow-up care. The launch of this centre is expected to strengthen clinical efforts to address complex cases of hypertension and enhance long-term cardiovascular health outcomes.